Alterola Biotech, Inc.

Equities

ABTI

US02152V1035

Biotechnology & Medical Research

Market Closed - OTC Markets Other stock markets 09:30:00 2024-04-22 am EDT			5-day change	1st Jan Change
0.0037 ^USD	-31.48%		-31.48%	+2.78%

Feb. 20	Alterola Biotech, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	CI
2023	Alterola Biotech, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	CI

Alterola Biotech, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023

February 20, 2024 at 05:29 pm EST

Alterola Biotech, Inc. reported earnings results for the third quarter and nine months ended December 31, 2023. For the third quarter, the company reported net loss was USD 2.01 million compared to USD 0.534789 million a year ago.
For the nine months, net loss was USD 2.87 million compared to USD 1.72 million a year ago.

Latest news about Alterola Biotech, Inc.

Alterola Biotech, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	Feb. 20	CI
Alterola Biotech, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	Nov. 21	CI
Alterola Biotech, Inc. Announces Executive Changes	23-10-17	CI
Alterola Biotech, Inc. Reports Earnings Results for the First Quarter Ended June 30, 2023	23-08-15	CI
Alterola Biotech, Inc. Reports Earnings Results for the Full Year Ended March 31, 2023	23-07-10	CI
Alterola Biotech, Inc. Auditor Raises 'Going Concern' Doubt	23-07-09	CI
Alterola Biotech, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022	23-02-14	CI
Alterola Biotech, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022	22-11-21	CI
Alterola Biotech, Inc. Executive Changes	22-10-07	CI
Alterola Biotech, Inc. Appoints Terry Rafih as A Member of Board of Directors	22-10-07	CI
Bright Green Corporation completed the acquisition of 25% stake in Alterola Biotech, Inc. (OTCPK : ABTI) from Phytotherapeutix Holdings Limited, Equipped 4 Holdings Limited and T.P.R. Global Service Srl.	22-10-03	CI
Sector Update: Health Care Stocks Rebound Slightly in Late Trade, Pare Losses	22-08-30	MT
Sector Update: Health Care Stocks Dropping Tuesday Afternoon	22-08-30	MT
Bright Green Corporation has signed a letter of intent to acquire a 25% stake in Alterola Biotech, Inc. (OTCPK : ABTI) from Phytotherapeutix Holdings Limited, Equipped 4 Holdings Limited and T.P.R. Global Service Srl for $4 million.	22-08-29	CI
Alterola Biotech, Inc. Reports Earnings Results for the First Quarter Ended June 30, 2022	22-08-18	CI
Alterola Biotech, Inc. Reports Earnings Results for the Full Year Ended March 31, 2022	22-06-10	CI
Alterola Biotech, Inc. Auditor Raises 'Going Concern' Doubt	22-06-09	CI
Alterola Biotech, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2021	22-03-01	CI
Alterola Biotech, Inc. Announces Removal of Lalit Kumar Verma as A Director	21-12-10	CI
Alterola Biotech, Inc. completed the acquisition of the assets from C2 Wellness Corporation.	21-12-01	CI
Alterola Biotech, Inc. signed an agreement to acquire the assets from C2 Wellness Corporation for $6.4 million.	21-11-15	CI
Alterola Biotech, Inc. Auditor Raises 'Going Concern' Doubt	21-10-18	CI
Alterola Biotech : Board Replaces Outgoing CFO Larson Elsmore With Timothy Rogers as Interim CFO	21-10-05	MT
Alterola Biotech, Inc. Announces Executive Changes	21-10-05	CI
Alterola Biotech, Inc. Announces Executive Changes	21-10-05	CI

Chart Alterola Biotech, Inc.

Duration

Period

More charts

Company Profile

Alterola Biotech, Inc. is a pharmaceutical company. The Company is engaged in the development of cannabinoid, cannabinoid-like, and non-cannabinoid pharmaceutical active pharmaceutical ingredients (APIs); pharmaceutical medicines made from cannabinoid, cannabinoid-like, and non-cannabinoid APIs; and European food approval of cannabinoid-based, cannabinoid-like, and non-cannabinoid ingredients and products. The Company has three areas of focus: development of regulated pharmaceuticals (human and animal health) and regulated food products; production of APIs and food-grade ingredients; and formulation, and drug delivery, providing bioavailability, solubility, and stability. It also focuses on developing new medicines from various sources, including botanical, traditional chemical synthesis, and biosynthetic methodologies. Its wholly owned subsidiaries include ABTI Pharma Ltd, Phytotherapeutix Ltd, and Ferven Ltd.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
ALTEROLA BIOTECH, INC.	+2.78%	5.12M
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103B
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.28B
ARGENX SE	+1.69%	22.15B
BIONTECH SE	-17.37%	21.02B
GENMAB A/S	-9.30%	18.15B
WUXI APPTEC CO., LTD.	-41.01%	16.73B
BEIGENE, LTD.	-14.85%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.68B
SAREPTA THERAPEUTICS, INC.	+33.54%	12.17B

Bio Therapeutic Drugs